CalciMedica (NASDAQ:CALC) Raised to Moderate Buy at Singular Research

CalciMedica (NASDAQ:CALC) was upgraded by Singular Research to a “moderate buy” rating in a research report issued on Friday, Zacks.com reports.

A number of other equities analysts have also recently issued reports on CALC. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of CalciMedica in a research report on Thursday, June 27th. Oppenheimer reiterated an “outperform” rating and set a $14.00 price target on shares of CalciMedica in a report on Monday, April 1st.

CalciMedica Stock Performance

Shares of NASDAQ CALC opened at $4.25 on Friday. CalciMedica has a 52 week low of $1.75 and a 52 week high of $8.38. The stock has a market capitalization of $45.69 million, a P/E ratio of -1.98 and a beta of 1.28. The stock’s fifty day moving average is $5.26 and its 200 day moving average is $4.63.

CalciMedica (NASDAQ:CALC) last issued its earnings results on Monday, May 13th. The company reported ($0.43) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.07. Equities research analysts forecast that CalciMedica will post -2.05 earnings per share for the current year.

Insider Activity

In other CalciMedica news, Director Robert N. Wilson bought 8,443 shares of the business’s stock in a transaction that occurred on Thursday, June 27th. The shares were acquired at an average cost of $3.23 per share, for a total transaction of $27,270.89. Following the transaction, the director now directly owns 258,918 shares in the company, valued at $836,305.14. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 53.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Meritage Portfolio Management raised its position in shares of CalciMedica by 360.0% during the fourth quarter. Meritage Portfolio Management now owns 46,000 shares of the company’s stock worth $132,000 after acquiring an additional 36,000 shares during the last quarter. BML Capital Management LLC boosted its position in shares of CalciMedica by 63.8% during the 4th quarter. BML Capital Management LLC now owns 145,424 shares of the company’s stock valued at $416,000 after purchasing an additional 56,643 shares in the last quarter. Finally, Hudson Bay Capital Management LP acquired a new stake in CalciMedica during the third quarter worth approximately $432,000.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.